Study S002426

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)

ClinicalTrials.gov record

Registration

Registration: NCT07776509
Acronym: SELENE 3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 500
Start: 2026-08-24
Primary completion: 2028-08-09
Lead sponsor: AstraZeneca
Conditions: Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2
Interventions: DRUG:Lenbelintide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: CTIS:2025-523295-23-00; REGISTRY:159494; NIH:2025

Registered primary outcomes

Percent change in body weight from baseline at 68 weeks of treatment [68 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.